Improvement of Memory in Mild Cognitive Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Clinical Trial will systematically examine the feasibility of remote, caregiver-led tACS for older adults with memory deficits and evaluate whether repeated tACS leads to sustained improvement of neuronal activity and memory functions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Understanding Brain Mechanisms Involved in Autobiographical Memory

NCT05710549

Mild Cognitive Impairment Alzheimer Disease Memory Loss

RECRUITING NA

Effects of tACS Combined With CCT for Patients With MCI

NCT04135742

Mild Cognitive Impairment

UNKNOWN NA

Memory Functions in Mild Alzheimer's Disease

NCT04785053

Alzheimer Disease

COMPLETED NA

Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS

NCT02110043

Mild Cognitive Impairment (MCI)

COMPLETED NA

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults

NCT06733714

Cognitive Dysfunction Alzheimer Disease Mild Cognitive Impairment +8 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed investigation will systematically examine the feasibility and efficacy of remote, caregiver-led tACS for older adults with memory decline. This study will provide data to support the safety and effectiveness of home-based tACS in this population and will lead to future research to increase access to tACS as a part of memory decline prevention and treatment for older adults.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcranial alternating current stimulation (tACS)

The randomized, sham-controlled, parallel-arm, double-blind clinical trial will include 4 weeks of daily, home-based stimulation sessions. MCI patients will be randomly assigned to the active or sham group.

Group Type EXPERIMENTAL

transcranial alternating current stimulation (tACS)

Intervention Type DEVICE

tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.

neurophysiological (hdEEG)

At the baseline and after 4 weeks, MCI patients will be evaluated in the laboratory using hdEEG.

Group Type EXPERIMENTAL

high-density electroencephalography (hdEEG)

Intervention Type DEVICE

EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.

clinical measures (MoCA)

At the baseline and after 4 weeks, MCI patients will be evaluated in the laboratory using MoCA.

Group Type EXPERIMENTAL

Montreal Cognitive Assessment (MoCA)

Intervention Type DIAGNOSTIC_TEST

Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcranial alternating current stimulation (tACS)

tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.

Intervention Type DEVICE

high-density electroencephalography (hdEEG)

EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.

Intervention Type DEVICE

Montreal Cognitive Assessment (MoCA)

Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Mild Cognitive Impairment (MCI) patients

* age ≥ 55 years old
* clinical diagnosis of mild cognitive impairment (MCI) based on a comprehensive clinical assessment and standard neuropsychological examination including tests of language, visuospatial thinking, executive functions, and memory
* confirmation of diagnosis will be made by Prof. Paul Unschuld, the study MD, based on a participant's cognitive evaluation and history
* understanding of the informed consent
* able and willing to comply with all study requirements
* informed consent form was signed
* women of childbearing potential (WOCBP) must perform a pregnancy test during screening

Caregiver

* minimum 21 years of age
* self-reported computer/tablet proficiency
* willingness to learn how to use tACS
* availability during the study period to administer tACS to the participant
* informed consent form was signed
* women of childbearing potential (WOCBP) must perform a pregnancy test during screening

Exclusion Criteria

Mild Cognitive Impairment (MCI) patients

* age \< 55 years old
* any current diagnosis of a psychiatric disorder (e.g., schizophrenia, bipolar disorder, depressive disorder)
* other than MCI, any history of other progressive or genetic neurologic disorder (e.g., Parkinson's disease, multiple sclerosis, tubular sclerosis) or acquired neurological disease (e.g., stroke, traumatic brain injury, tumor), including intracranial lesions
* history of head trauma resulting in prolonged loss of consciousness
* current history of poorly controlled headaches including chronic medication for migraine prevention
* history of fainting spells of unknown or undetermined etiology that might constitute seizures
* history of seizures, diagnosis of epilepsy
* any unstable medical condition or chronic uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
* contraindication for undergoing MRI or receiving tACS
* any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g., MRI compatible joint replacement)
* any skin problems, such as dermatitis, psoriasis, or eczema
* any electrically, magnetically, or mechanically activated implanted devices such as a pacemaker, intracranial electrodes, implanted defibrillators, medication pumps, nerve stimulators, vascular clips, or any other prosthesis in the brain
* any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease, or active neoplasia
* pregnant women
* adults lacking capacity for consent

Caregiver

* insufficient understanding of study procedures
* poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tACS

Minimum Eligible Age

55 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes